Milk-alkali syndrome induced by 1,25(OH)2D in a patient with hypoparathyroidism.
Milk-alkali syndrome was first described 70 years ago in the context of the treatment of peptic ulcer disease with large amounts of calcium and alkali. Although with current ulcer therapy (H-2 blockers, omeprazole, and sucralfate), the frequency of milk-alkali syndrome has decreased significantly, the classic triad of hypercalcemia, alkalosis, and renal impairment remains the hallmark of the syndrome. Milk-alkali syndrome can present serious and occasionally life-threatening illness unless diagnosed and treated appropriately. This article presents a patient with hypoparathyroidism who was treated with calcium carbonate and calcitriol resulting in two admissions to the hospital for milk-alkali syndrome. The patient was successfully treated with intravenous pamidronate on his first admission and with hydrocortisone on the second. This illustrates intravenous pamidronate as a valuable therapeutic tool when milk-alkali syndrome presents as hypercalcemic emergency.
Tal
A
A
Department of Medicine University of Missouri, Kansas City 64108, USA.
Powers
K
K
D000368:Aged; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D002117:Calcitriol / Q000009:adverse effects*; D002119:Calcium Carbonate / Q000009:adverse effects*; D004164:Diphosphonates / Q000627:therapeutic use; D004630:Emergencies; D005260:Female; D006801:Humans; D006854:Hydrocortisone / Q000627:therapeutic use; D006934:Hypercalcemia / Q000139:chemically induced* / Q000188:drug therapy*; D007011:Hypoparathyroidism / Q000188:drug therapy; D000077268:Pamidronate
D000893:Anti-Inflammatory Agents; D004164:Diphosphonates; D002117:Calcitriol; D002119:Calcium Carbonate; D000077268:Pamidronate; D006854:Hydrocortisone